Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.31 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL149728 | 0.87 | APOBEC3G (0.43) | FFAR1APOBEC3GGAAPDCD1CD274 | |
| SCHEMBL5403277 | 0.81 | APOBEC3G (0.39) | FFAR1APOBEC3GPDCD1CD274TSHR | |
| Pyridine SCHEMBL2806204 | 0.76 | HDAC8 (0.37) | FFAR1HDAC8TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL2807658 | 0.72 | HDAC8 (0.37) | HDAC8TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL1477186 | 0.72 | TSHR (0.39) | GAAHDAC8TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL1477752 | 0.70 | TSHR (0.38) | GAAHDAC8TSHRNAPRTTDP1 | |
| SCHEMBL5750300 | 0.70 | APOBEC3G (0.43) | FFAR1APOBEC3GGAAPDCD1CD274 | |
| SCHEMBL3037715 | 0.69 | APOBEC3G (0.34) | FFAR1APOBEC3GPDCD1CD274 | |
| SCHEMBL9862093 | 0.69 | HSPA5 (0.40) | CYP1A2 | |
| Pyridine SCHEMBL3839470 | 0.69 | FFAR1 (0.40) | FFAR1MEN1KMT2AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110044943-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| WO-2010081145-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GLAXOSMITHKLINE LLC (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2178877-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GlaxoSmithKline LLC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20100029655-A1 | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them | LEIVERS MARTIN ROBERT | 2010-02-04 | — | — | US | disclosed |
| WO-2010006096-A1 | PROCESSES FOR THE PREPARATION OF ANTI-VIRAL COMPOUNDS AND COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090074717-A1 | Anti-viral compounds, compositions, and methods of use | GLAXOSMITHKLINE LLC | 2009-03-19 | — | — | US | disclosed |
| WO-2009011787-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074717-A1 | Anti-viral compounds, compositions, and methods of use | HAVCR2, SARS1, RPL35 | FFAR1 4532/4885APOBEC3G 517/4885GAA 107/4885 |
| US-20110044943-A1 | Anti-Viral Compounds, Compositions, And Methods Of Use | HAVCR2, SARS1, RPL35 | FFAR1 4532/4885APOBEC3G 517/4885GAA 107/4885 |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HAVCR2, SARS1, RPL35 | FFAR1 4532/4885APOBEC3G 517/4885GAA 107/4885 |
| US-20100029655-A1 | Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them | RPL35, HAVCR2, RPL5 | FFAR1 4845/4885APOBEC3G 184/4885GAA 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.